All In MedTech

PMA device

Medtronic Evolut FX System

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

1

PMA pathway

Device trials

9

Naming "Evolut FX"

MAUDE reports

11,866

Brand "Evolut FX", since 2015

PubMed studies

79

Mentioning "Evolut FX"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Medtronic Evolut FX System

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 1 of 1 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Evolut FX", any status and sponsor, newest update first.

Open in Trial Radar
  • Erasmus Medical CenterAcademic, hospital or other

    NCT04843072 · 600 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2028

    Device: EVOLUT R/PRO/PRO+/FX bioprosthesis; Edwards Sapien S3/Ultra bioprosthesis and 1 more · For: Valve Heart Disease

    Sites: Los Angeles, California; Vienna, Austria; Vancouver, Canada · 14 sites in all

  • Evolut™ EXPAND TAVR II Pivotal TrialPivotal-lookingActive, not recruiting

    Medtronic CardiovascularPublic (MDT)

    NCT05149755 · 650 participants (planned) · Start Apr 27, 2022 · Primary completion Sep 2027

    Device: Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) · For: Moderate Aortic Valve Stenosis

    Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 94 sites in all

  • Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.Pivotal-lookingActive, not recruiting

    Christian Juhl TerkelsenAcademic, hospital or other

    NCT06470022 · 1,370 participants · Start Aug 9, 2024 · Primary completion Jul 14, 2027

    Device: Medtronic Evolut FX; Edwards Sapien 3 Ultra Resilia · For: Aortic Stenosis

    Sites: Aarhus, Denmark

6 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Evolut FX", and for the whole product code for context.

This brand

11,866 reports: 3,585 malfunction, 6,889 injury, 1,392 death

Whole product code NPT

77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

1 more recall records with a free account

Published research

The most relevant PubMed records for "Evolut FX"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code NPT.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.